Group 1 - The core viewpoint of the announcement is the assurance of the board of directors regarding the authenticity, accuracy, and completeness of the content, with legal responsibility for any false statements or omissions [2][3] - The board meeting was held on August 18, 2025, with all six directors present, complying with the relevant regulations of the Company Law and Articles of Association [2] - The 2025 semi-annual report and summary were approved by the board of directors after review by the audit committee, with unanimous support from all voting directors [2]

Core Viewpoint - Guangyuyuan Traditional Chinese Medicine Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, reflecting a robust growth strategy and market positioning in the traditional Chinese medicine sector [2][13]. Company Overview and Financial Indicators - The company achieved an operating income of 779.28 million yuan, a year-on-year increase of 18.14% compared to 659.60 million yuan in the same period last year [2]. - The total profit reached 86.63 million yuan, up 18.90% from 72.86 million yuan in the previous year [2]. - The net profit attributable to shareholders was 76.86 million yuan, representing a 28.95% increase from the previous year [13]. - The company's total assets amounted to 2.45 billion yuan, with net assets attributable to shareholders at 1.65 billion yuan, reflecting a 7.83% increase [2]. Business Operations - The company primarily engages in the production and sale of traditional Chinese medicine products, categorized into three main segments: traditional Chinese medicine, premium Chinese medicine, and health wine [6]. - Guangyuyuan has a rich history, being one of the oldest traditional Chinese medicine brands, with core products recognized as national intangible cultural heritage [6]. - The company employs a dual procurement strategy, utilizing both tender and direct purchasing methods to ensure quality and cost-effectiveness in raw material sourcing [6]. Market Strategy and Growth - The company is focused on a "1541" strategic framework aimed at enhancing product quality and market penetration, with a strong emphasis on brand development and cultural heritage [13]. - Guangyuyuan has expanded its retail presence, adding 43 new stores, bringing the total to 505 by the end of June 2025 [13]. - The company is leveraging digital transformation to integrate online and offline sales channels, enhancing customer experience and operational efficiency [13]. Industry Context - The pharmaceutical manufacturing industry is undergoing significant transformation, driven by government policies aimed at improving quality and safety standards in traditional Chinese medicine [6]. - Recent regulatory changes are expected to enhance the market environment, promoting fair pricing and transparency in drug procurement [11]. - The industry is also witnessing a shift towards high-quality development, with an emphasis on innovation and internationalization of traditional Chinese medicine [6][8].

Core Viewpoint - Guangyuyuan Traditional Chinese Medicine Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with increases in revenue, profit, and net assets compared to the previous year [1][2]. Financial Performance - Total assets reached approximately 2.45 billion RMB, an increase of 7.83% from the end of the previous year [1]. - Net assets attributable to shareholders increased by 4.90% to approximately 1.65 billion RMB [1]. - Operating revenue for the period was approximately 779.28 million RMB, reflecting an 18.14% increase compared to 659.60 million RMB in the same period last year [1]. - Total profit rose by 18.90% to approximately 86.63 million RMB, up from 72.86 million RMB [1]. - Net profit attributable to shareholders increased by 28.95% to approximately 76.86 million RMB, compared to 59.60 million RMB in the previous year [1]. - The net cash flow from operating activities was approximately 246.06 million RMB, a significant increase of 51.65% from 162.26 million RMB [1]. - The weighted average return on equity improved to 4.78%, up by 0.87 percentage points from 3.91% [1]. Shareholder Information - The largest shareholder, Shennong Technology Group Co., Ltd., holds 15.17% of the shares, amounting to approximately 74.23 million shares [2]. - Other notable shareholders include Jiang Shibo with 1.67% (approximately 8.19 million shares) and Hong Kong Central Clearing Limited with 1.15% (approximately 5.62 million shares) [2]. - The total number of shareholders as of the report date was 63,497 [1].

证券代码：600771 证券简称：广誉远 编号：临 2025-014 《公司 2025 年半年度报告及摘要》已经董事会审计委员会审议通过，同意提交公 司董事会审议。 表决情况：同意 6 票，反对 0 票，弃权 0 票。 特此公告。 广誉远中药股份有限公司董事会 二〇二五年八月十八日 广誉远中药股份有限公司 第八届董事会第十六次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十六次会议于 2025 年 8 月 8 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2025 年 8 月 18 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及《公 司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了《公司 2025 年半年度报告及摘要》。 ...

（文章来源：证券日报） 证券日报网讯 8月18日晚间，广誉远发布公告称，2025年半年度公司实现营业收入779，283，565.11 元，同比增长18.14%；归属于上市公司股东的净利润为76，857，103.56元，同比增长28.95%。 ...

报告期内，新增43家终端门店，截至2025年6月30日，终端门店总数共计505家。 公告显示，依据产品定位和销售渠道不同，公司医药工业主要包括传统中药、精品中药和养生酒三大板 块。公司现有丸剂、散剂、片剂、硬胶囊剂、颗粒剂、合剂、酒剂及煎膏剂（膏滋）8种剂型，104个药 品注册批件、1个保健品注册批件、1个食品许可批件、1个白酒许可批件、264个国内商标和28项专利技 术。 截至2025年6月30日，公司总资产为24.54亿元，归属于上市公司股东净资产为16.47亿元。 8月18日，广誉远发布2025年半年度报告。 报告显示，报告期内，公司实现营业收入7.79亿元，同比增长18.14%；归属于上市公司股东净利润为 7,685.71万元，同比上涨28.95%。 ...

智通财经APP讯，广誉远(600771.SH)发布2025年半年度报告，该公司营业收入为7.79亿元，同比增长 18.14%。归属于上市公司股东的净利润为7685.71万元，同比增长28.95%。归属于上市公司股东的扣除 非经常性损益的净利润为6799.86万元，同比增长21.76%。基本每股收益为0.16元。 ...

（文章来源：每日经济新闻） 广誉远8月18日晚间发布公告称，公司第八届第十六次董事会会议于2025年8月18日以通讯方式召开。会 议审议了《公司2025年半年度报告及摘要》等文件。 ...

（文章来源：每日经济新闻） 广誉远8月18日晚间发布半年度业绩报告称，2025年上半年营业收入约7.79亿元，同比增加18.14%；归 属于上市公司股东的净利润约7686万元，同比增加28.95%；基本每股收益0.16元，同比增加33.33%。 ...

证券代码：600771 证券简称：广誉远 编号：临 2025-014 表决情况：同意 6 票，反对 0 票，弃权 0 票。 广誉远中药股份有限公司 第八届董事会第十六次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十六次会议于 2025 年 8 月 8 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2025 年 8 月 18 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及《公 司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了《公司 2025 年半年度报告及摘要》。 《公司 2025 年半年度报告及摘要》已经董事会审计委员会审议通过，同意提交公 司董事会审议。 特此公告。 广誉远中药股份有限公司董事会 二〇二五年八月十八日 1 ...